In Vivo CAR
Redefining Cancer Immunotherapy with BioDrone™-Mediated In Vivo Reprogramming
Technology Overview
Conventional CAR-T therapy requires complex and costly processes involving cell extraction and ex vivo expansion. Carus Bio instead delivers CDVs loaded with CAR-mRNA directly into the body, enabling immune cells to express CAR receptors and target cancer cells.
Mechanism
CDVs carrying CAR-mRNA precisely target immune cells such as T cells and macrophages and deliver genetic instructions intracellularly.
Transformation
The reprogrammed immune cells express CAR receptors and transform into powerful CAR-T or CAR-M cells.
Efficiency
These engineered immune cells migrate to tumor sites and selectively eliminate cancer cells.
Competitive Advantages of the BioDrone™ Platform
| BioDrone™ Platform | VS | Conventional Ex Vivo CAR-T |
|---|---|---|
| Off-the-shelf Mass production possible |
Manufacturing | Patient-specific Customized production |
| Immediate treatment | Waiting Time | 4–6 weeks |
| Transient expression Higher safety |
Safety | Permanent modification Long-term risks |
| Non-invasive | Patient Convenience | Invasive procedures required |
| Cost-efficient | Cost | Very high cost |
Partnering Inquiry
The BioDrone™-based In Vivo CAR platform is poised to transform cancer treatment.
We are seeking partners for collaborative research and strategic partnerships.
COPYRIGHT ⓒ CARUS Bio Inc. ALL RIGHTS RESERVED.